{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/lung-cancer-peer-reviewed-journal-articles-featuring-fortrea-oncologists#webpage",
"url": "https://www.fortrea.com/insights/lung-cancer-peer-reviewed-journal-articles-featuring-fortrea-oncologists",
"name": "Lung Cancer: Peer-reviewed Journal Articles Featuring Fortrea Oncologists",
"description": "This Fortrea infosheet explores how immunotherapy in lung cancer is evolving through precision medicine, translational lung cancer research, and oncology evidence generation across modern clinical development programs. The content focuses on scientific and clinical perspectives related to immunotherapy in lung cancer treatment, genomic alterations in lung cancer, personalized lung cancer treatment approaches, and emerging advanced NSCLC treatment strategies within precision oncology research. The infosheet highlights how lung cancer in the era of precision medicine is increasingly shaped by biomarker-driven approaches, translational oncology insights, and individualized treatment planning designed to support more targeted therapeutic decision-making. Fortrea oncologists discuss ongoing developments in lung cancer clinical development, translational research integration, and precision medicine in lung cancer to support future oncology innovation and evolving treatment strategies. By integrating scientific evidence generation with immunotherapy research and precision oncology insights, the infosheet provides a broader understanding of current trends shaping lung cancer treatment and clinical development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Lung Cancer: Peer-reviewed Journal Articles Featuring Fortrea Oncologists",
"item": "https://www.fortrea.com/insights/lung-cancer-peer-reviewed-journal-articles-featuring-fortrea-oncologists"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/lung-cancer-peer-reviewed-journal-articles-featuring-fortrea-oncologists#infosheet",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/lung-cancer-peer-reviewed-journal-articles-featuring-fortrea-oncologists#webpage"
},
"headline": "Immunotherapy in Lung Cancer and the Shift Toward Precision Medicine | Fortrea Infosheet",
"description": "This Fortrea infosheet explores how immunotherapy in lung cancer is evolving through precision medicine, translational lung cancer research, and oncology evidence generation across modern clinical development programs. The content focuses on scientific and clinical perspectives related to immunotherapy in lung cancer treatment, genomic alterations in lung cancer, personalized lung cancer treatment approaches, and emerging advanced NSCLC treatment strategies within precision oncology research. The infosheet highlights how lung cancer in the era of precision medicine is increasingly shaped by biomarker-driven approaches, translational oncology insights, and individualized treatment planning designed to support more targeted therapeutic decision-making. Fortrea oncologists discuss ongoing developments in lung cancer clinical development, translational research integration, and precision medicine in lung cancer to support future oncology innovation and evolving treatment strategies. By integrating scientific evidence generation with immunotherapy research and precision oncology insights, the infosheet provides a broader understanding of current trends shaping lung cancer treatment and clinical development.",
"genre": "Info Sheet",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-07-12",
"dateModified": "2025-07-12",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/lung-cancer-peer-reviewed-fortrea-oncologists-10-04-2026.pdf",
"encodingFormat": "application/pdf"
}
}
]
}